Leading a Biotech Through Crisis
This article was originally published in Start Up
Executive Summary
Given the cyclical nature of the biotech industry, companies--both public and private--are forced to weather financing storms every few years. During lean times, one strategy is to cut operations to create the basis for a financing event and stave off the inevitable cash cliff. But a company focusing all its efforts on one, or at most a few, projects has very little to fall back on should its lead opportunity fail. And the equity markets may not come back in time. BioTransplant's CEO-Donald Hawthorne, brought in to save the company, understood from the beginning that companies with just a few months of cash left tend to fail. His challenge: to avoid failure, while at the same time maximizing the chance that in the event of bankruptcy, at least some of the assets of the company could create additional value.You may also be interested in...
Biotechs on the Brink Choose Last-Minute Deals, Not Liquidation
Biotech Layoffs Hit Hardest In Discovery
BioTransplant: Turned on to Tolerance
Need a specific report? 1000+ reports available
Buy Reports